Protalix BioTherapeutics (PLX) FCF Margin Growth (3y) (2013 - 2026)
Protalix BioTherapeutics (PLX) FCF Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15,064.00 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 723.00 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1,409.00 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Protalix BioTherapeutics | 190.95 Mn | 180.16 Mn | 29.62 Mn | 9,767.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9,767.00 |
| Dec 31, 2025 | 6,133.00 |
| Sep 30, 2025 | 4,006.00 |
| Jun 30, 2025 | 5,109.00 |
| Mar 31, 2025 | -1,758.00 |
| Dec 31, 2024 | 6,835.00 |
| Sep 30, 2024 | 3,721.00 |
| Jun 30, 2024 | -12,362.00 |
| Mar 31, 2024 | 19,813.00 |
| Dec 31, 2023 | 7,541.00 |
| Sep 30, 2023 | -3,656.00 |
| Jun 30, 2023 | 8,719.00 |
| Mar 31, 2023 | -148.00 |
| Dec 31, 2022 | -679.00 |
| Sep 30, 2022 | -4,038.00 |
| Jun 30, 2022 | -4,168.00 |
| Mar 31, 2022 | 3,467.00 |
| Dec 31, 2021 | 18,995.00 |
| Sep 30, 2021 | -205,993.00 |
| Jun 30, 2021 | 38,335.00 |